• Explore /
  • Poster
  • / A randomized, open-label, phase II study of azacitidine (AZA) in combination with durvalumab in patients (pts) with previously untreated higher-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) ineligible for hematopoietic stem cell transplantation (HSCT).

A randomized, open-label, phase II study of azacitidine (AZA) in combination with durvalumab in patients (pts) with previously untreated higher-risk myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) ineligible for hematopoietic stem cell transplantation (HSCT).

Abstract Poster

Authors

null

Lewis R. Silverman

Icahn School of Medicine at Mount Sinai, New York, NY

Lewis R. Silverman , Hartmut Dohner , Herve Dombret , Ghulam J. Mufti , Richard M. Stone , Shelonitda Rose , Torsten Gerike , Frederic Camus , Pierre Fenaux

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Sub Track

Myelodysplastic Syndromes (MDS)

Clinical Trial Registration Number

NCT02775903

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS7074)

DOI

10.1200/JCO.2017.35.15_suppl.TPS7074

Abstract #

TPS7074

Poster Bd #

270a

Abstract Disclosures

Similar Posters

First Author: Meixia Chen

First Author: Jing Wang

First Author: Antoine Italiano

First Author: Anthony B. El-Khoueiry